Mind.Px brings personalized medicine to psoriasis patients by improving pre-treatment biologic drug class choice with >90% positive predictive value
SAN DIEGO – October 21, 2021 – Mindera Health, developers of the ground-breaking Dermal Intelligence™ platform that is the first realization of personalized medicine in psoriasis, announced the enrollment of the first patient in the MATCH Study. MATCH is a 16-week randomized clinical utility evaluation of the pre-treatment impact of Mind.Px on biologic drug response rates in patients suffering from psoriasis. The 200 patient study will include approximately 20 sites throughout the US.
According to a recent publication reporting data from the largest independent psoriasis registry (CorEvitas),[1] real-world patient response rates to hyper-expensive biologics were observed to be approximately 52%. These low response rates…